| Index | — | P/E | — | EPS (ttm) | -0.43 | Insider Own | 10.96% | Shs Outstand | 129.85M | Perf Week | 17.35% |
| Market Cap | 1.89B | Forward P/E | 109.98 | EPS next Y | 0.13 | Insider Trans | — | Shs Float | 83.72M | Perf Month | 3.27% |
| Enterprise Value | 1.91B | PEG | — | EPS next Q | -0.14 | Short Float | 3.90% | Perf Quarter | -1.76% | ||
| Income | -58.00M | P/S | 15.60 | EPS this Y | — | Short Ratio | 15.52 | Perf Half Y | -9.13% | ||
| Sales | 121.00M | P/B | 3.32 | EPS next Y | — | ROA | -7.44% | Short Interest | 3.27M | Perf YTD | -19.40% |
| Book/sh | 4.37 | P/C | 18.33 | EPS next 5Y | — | ROE | -10.06% | 52W High | 21.50 -32.37% | Perf Year | -11.50% |
| Cash/sh | 0.79 | P/FCF | — | EPS past 3/5Y | — | ROIC | -16.74% | 52W Low | 11.89 22.29% | Perf 3Y | 521.37% |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | 147.30% 76.82% | Gross Margin | 78.30% | Volatility | 3.54% 3.11% | Perf 5Y | 15.40% |
| Dividend TTM | — | EV/Sales | 15.79 | EPS Y/Y TTM | — | Oper. Margin | -96.11% | ATR (14) | 0.68 | Perf 10Y | 69.07% |
| Dividend Ex-Date | — | Quick Ratio | 2.09 | Sales Y/Y TTM | 572.22% | Profit Margin | -46.79% | RSI (14) | 53.81 | Recom | 2.73 |
| Dividend Gr. 3/5Y | — | Current Ratio | 2.43 | EPS Q/Q | 59.38% | SMA20 | 7.25% | Beta | 2.19 | Target Price | 39.00 |
| Payout | 0.00% | Debt/Eq | 0.22 | Sales Q/Q | 400.00% | SMA50 | -2.29% | Rel Volume | 1.10 | Prev Close | 15.16 |
| Employees | 108 | LT Debt/Eq | 0.20 | Earnings | Mar 04 | SMA200 | -5.56% | Avg Volume | 237.88K | Price | 14.54 |
| IPO Date | Jan 20, 2010 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -71.39% 136.14% | Net Debt/EBITDA | — | Volume | 261,308 | Change | -4.09% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-27-26 | Reiterated | Piper Sandler | Overweight | $11 → $39 |
| Nov-25-25 | Upgrade | Jefferies | Hold → Buy | |
| Jul-18-25 | Downgrade | Jefferies | Buy → Hold | |
| Dec-23-24 | Downgrade | Jefferies | Buy → Hold | |
| Sep-24-24 | Reiterated | Maxim Group | Hold | $12 |
| Jul-23-24 | Upgrade | Piper Sandler | Neutral → Overweight | $11 |
| Aug-30-23 | Upgrade | Jefferies | Hold → Buy | |
| Aug-06-23 | Downgrade | Maxim Group | Buy → Hold | |
| Aug-03-23 | Downgrade | Piper Sandler | Overweight → Neutral | |
| Aug-03-23 | Downgrade | William Blair | Outperform → Market Perform |
Mesoblast Limited is a biopharmaceutical firm dedicated to the development and commercialization of allogeneic cell-based therapies. Its global presence extends across the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company addresses a broad spectrum of medical conditions, including cardiovascular, spinal orthopedic disorders, oncology, hematology, and immune-mediated and inflammatory diseases. At the core of its innovation is a proprietary regenerative medicine platform utilizing specialized mesenchymal lineage cells. Currently, several of Mesoblast's leading product candidates are undergoing Phase III clinical trials: remestemcel-L, designed for severe, steroid-refractory acute graft versus host disease and acute respiratory distress syndrome associated with COVID-19; Rexlemestrocel-L, aimed at advanced chronic heart failure; and MPC-06-ID, intended for chronic low back pain stemming from degenerative disc disease. Additionally, MPC-300-IV is being developed for biologic-refractory rheumatoid arthritis and diabetic nephropathy. The company has cultivated strategic partnerships to advance its pipeline and market reach. These collaborations include Tasly Pharmaceutical Group for the distribution of MPC-150-IM (heart failure) and MPC-25-IC (heart attacks) in China; JCR Pharmaceuticals Co. Ltd. for therapies addressing wound healing in patients with epidermolysis bullosa; and Grünenthal for the development and commercialization of cell therapy solutions for chronic low back pain. Mesoblast Limited was established in 2004 and maintains its headquarters in Melbourne, Australia.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2026 6/30/2026 | FY 2025 6/30/2025 | FY 2024 6/30/2024 | FY 2023 6/30/2023 | FY 2022 6/30/2022 | FY 2021 6/30/2021 | FY 2020 6/30/2020 | FY 2019 6/30/2019 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 121 | 121 | 17 | 6 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 20 | 19 | 5 | 41 | — | — | — | — | — | |
| Gross Profit | 96 | 102 | 12 | -35 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 56 | 55 | 39 | 24 | — | — | — | — | — | |
| Research and Development | 98 | 98 | 35 | 25 | — | — | — | — | — | |
| Other Operating Expense | 0 | 0 | 1 | 0 | — | — | — | — | — | |
| Operating Income | -118 | -52 | -62 | -84 | — | — | — | — | — | |
| Interest Expense | 12 | 24 | 23 | 21 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 72 | 18 | -16 | 17 | — | — | — | — | — | |
| Net Income Before Taxes | -58 | -57 | -102 | -88 | — | — | — | — | — | |
| Income Taxes | 0 | 1 | 0 | 0 | — | — | — | — | — | |
| Consolidated Net Income | -58 | -58 | -102 | -88 | — | — | — | — | — | |
| Net Income From Continuing Operations | -58 | -58 | -102 | -88 | — | — | — | — | — | |
| Net Income | -58 | -58 | -102 | -88 | — | — | — | — | — | |
| EPS (Recurring) | -0.43 | -0.45 | -0.84 | -0.89 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -0.43 | -0.45 | -0.84 | -0.89 | — | — | — | — | — | |
| EPS (Diluted) | -0.43 | -0.45 | -0.84 | -0.89 | — | — | — | — | — | |
| EBITDA | -44 | -43 | -74 | -53 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 15.62 | 14.42 | 77.51 | 112.37 | — | — | — | — | — | |
| Gross Margin | 79.34 | 84.30 | 70.59 | -583.33 | — | — | — | — | — | |
| Operating Margin | -97.52 | -42.98 | -364.71 | -1,400.00 | — | — | — | — | — | |
| Net Margin | -47.93 | -47.93 | -600.00 | -1,466.67 | — | — | — | — | — | |
| Shares Outstanding | 130 | 129 | 121 | 99 | — | — | — | — | — | |
| Market Capitalization | 1,890 | 1,745 | 1,318 | 674 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| George Gregory | Director, 10% Owner | Apr 09 '26 | Buy | 4.96 | 2,181,890 | 10,829,564 | 13,586,890 | Apr 13 |
| George Gregory | Director, 10% Owner | Apr 10 '26 | Buy | 1.48 | 2,324,072 | 3,439,627 | 8,324,072 | Apr 10 |
| George Gregory | Director, 10% Owner | Apr 04 '26 | Buy | 1.42 | 4,000,000 | 5,680,000 | 12,000,000 | Apr 10 |